Annual report pursuant to Section 13 and 15(d)

Going Concern and Management???s Plans (Details Narrative)

v3.19.1
Going Concern and Management’s Plans (Details Narrative) - USD ($)
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]      
Accumulated deficit $ (7,624,134) $ (3,859,086)  
Net income loss (3,765,047) (1,856,315)  
Net cash used in operating activities (3,707,914) (1,654,617)  
Cash and cash equivalents 1,740,961 $ 2,847,429 $ 1,071,894
Clinical Trial Funding commitment from investor capital $ 1,800,000